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Introduction
The incidence of splenic metastases secondary to colo-
rectal cancer is very low; these lesions have been more
frequently reported as secondary to breast, lung, and
ovarian cancer. Splenic metastases are particularly com-
mon in melanoma; their incidence has been reported as
being as high as 34% at autopsy [1]. Most cases of
secondary splenic metastases have been described in pa-
tients with tumors of the left colon while only few
cases being reported as originating from right colon tu-
mors (Table 1). The finding of a splenic mass in the
absence of a history of malignancy suggests a primary
lesion (lymphoma, hematoma, etc.), while a history of
oncological disease raises the possibility of a secondary
lesion [2].
Case Description
We report the case of a 76-year-old woman with a family
history positive for breast carcinoma (sister and daughter).
The patient underwent a left breast quadrantectomy in
March 2006 for ductal infiltrating carcinoma (pT1a pN0
pMx, C-erb B2: 3+, ER 80%, 80% PgR,MIB <10%) followed
by regional radiation and hormone therapy with letrozole for
5 years. She then went through standard follow-up.
In 2013, she underwent a colonoscopy and a CT scan
of the abdomen which showed a 3-cm thickening and
enhancement of the wall of the descending colon, com-
plicated by lumen substenosis. The liver and the spleen
were free of focal lesions. The CT also showed the pres-
ence of a saccular aneurysm of the splenic artery with a
maximum transverse diameter of 1.6 cm and partial cal-
cified thrombosis of the vessel wall. Some lymph nodes
in the portacaval region were increased in volume. The
patient underwent a left hemicolectomy in March 2013.
Histological examination of the surgical specimen re-
vealed an adenocarcinoma with a medium degree of dif-
ferentiation, infiltrating the wall up to the subserosal lay-
er with angiolymphatic but no perineural invasion. Two
out of the ten perirectal lymph nodes showed metastatic
involvement. The resection margins were free of tumor.
The staging was pT3 pN1b pMx—G2. The patient began
adjuvant chemotherapy in August 2013 following the
CAPOX protocol: oxaliplatin 130 mg/mq g1q21, capecit-
abine 1000 mg/mq g1-14q21 for six cycles (not eight
cycles for liver toxicity) until December 2013.
A follow-up chest abdomen CT scan performed at the be-
ginning of July 2015 showed the presence of a 1-cm-diameter
focal lesion in the lower third of the spleen in the subcapsular
region associated with mild capsular retraction. A subsequent
PETscan identified a 9-mm area of increased accumulation of
radium localized at the same intrasplenic location and sugges-
tive of secondary lesions. A splenectomy was performed in
September 2015 and the lesion appeared on gross examination
as a whitish nodule with a diameter of 1.6 × 1.5 × 1 cm, com-
pact in appearance and well circumscribed by the surrounding
parenchyma (Fig. 1). The lesion was found to be an
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adenocarcinoma with immunophenotypic profile compatible
with a secondary lesion from the digestive tract (Fig. 2a, b).
The pretreatment CT scan performed in October 2015 again
demonstrated the thrombosed saccular dilatation of the distal
third of the splenic artery. The patient began adjuvant chemo-
therapy with capecitabine in November 2015; to date,
21 months after splenectomy, she is in complete remission.
Discussion
The most common sites of metastases from colorectal cancer
are the regional lymph nodes, the liver, the lungs, and the
peritoneum. Splenic metastases are much rarer. Berge
demonstrated that the incidence of splenic metastases is ap-
proximately 7.1% in 7165 autopsies performed on subjects
who died with various cancer histotypes. The secondary le-
sions arising from the colon are 4.4% while those that origi-
nate from the rectum are 1.6% [3]. In most cases, the individ-
ual splenic metastases from colorectal carcinoma are asymp-
tomatic. Sometimes, they can be responsible for non-specific
symptoms such as malaise, weight loss, heartburn, pain in the
left abdominal upper quadrant, splenomegaly, and
hypersplenism. Rarely, it is possible to have spontaneous
splenic rupture or splenic abscess formation [4]. The diagnosis
is made by imaging studies during follow-up or during disease
staging. Possible explanations of the rarity of such splenic
lesions [5] are due both to anatomical and immunological
Table 1 Literature review of isolated metachronous splenic metastasis from colorectal carcinoma
Case n Year Pathology Primary tumor Stage Intervala CEA level
1 1969 Adeno Rectum III 48 Not specified
2 1982 Adeno Sigmoid III 48 A
3 1986 Adeno Cecum III 30 A
4 1992 Adeno Rectum II 60 A
5 1993 Adeno Left colon II 144 A
6 1997 Adeno Splenic flexure III 42 A
7 1997 Adeno Sigmoid II 24 A
8 1999 Adeno Rectum Not specified 12
9 1999 Adeno Sigmoid III 3 A
10 1999 Left colon
11 2000 Adeno Right colon III 36 A
12 2000 Adeno Not specified Not specified 108 A
13 2001 Adeno Sigmoid III 72 A
14 2001 Adeno Left colon IV 52 A
15 2001 Left colon
16 2001 Adeno Sigmoid III 23 A
17 2003 Adeno Left colon 72
18 2004 Adeno Sigmoid III 21 N
19 2004 Adeno Left colon
20 2006 Adeno Sigmoid colon
21 2006 Adeno Descending III 17 A
22 2008 Adeno Splenic flexure IV 36 A
23 2008 Adeno Traverse colon III 9 A
24 2008 Adeno Rectum III 18 A
25 2008 Adeno Sigmoid II 24 A
26 2009 Adeno Hepatic flexure III 60 A
27 2010 Adeno Splenic flexure III 24 A
28 2010 Adeno Ascending III 15 A
29 2011 Adeno Rectum III 15 N
30 2015 Adeno Cecum I 16 A
31 2016 Adeno Descending III 28 N
aDFI disease-free interval between treatment of primary tumor and diagnosis of the spleen metastasis
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contraction of splenic sinusoids, the absence of afferent lym-
phatic vessels within the splenic parenchyma, and the pres-
ence of a capsule which acts as a barrier for cell tumor could
reduce the probability that tumor emboli can be implanted in
the spleen. While, as regards the immunological characteris-
tics that could reduce the probability of metastatic emboliza-
tion in the spleen, these could be the production of an inhib-
itory factor that reduces the implantation and neoplastic cells
growth, as well as the particular microenvironment rich in
splenic monocytes, Kupffer cells, and Ig.
For these reasons, the exact etiopathogenetic mechanism is
uncertain but several hypotheses have been made. Idhuara [6]
argues that the metastatic spread occurs probably because of
blood reflux from the inferior mesenteric vein in the splenic
vein and from there to the spleen. This is in relation to the fact
that the localization of primary carcinoma in these patients is
mostly at the level of the left hemicolon. The literature sug-
gests that high levels of serum CEA are associated with iso-
lated splenic metastases from colorectal cancer. This is prob-
ably related to its biological functions: modulating the
immune response by reducing the humoral, lymphocytic,
and NK cell activity and facilitating the tumor cells adhesion
to visceral macrophages in the spleen [7].
We found only 30 cases of isolated splenic metasta-
ses secondary to colorectal tumors from the first report-
ed cases in 1969 up to 2016 (Table 1); none of these
had further metastatic localizations at the time of the
diagnosis. Most of the patients were asymptomatic,
and the diagnosis was made by radiological examina-
tions during follow-up. An increase in CEA level was
detected in most cases. From these studies, it is clear
that isolated splenic metastases from colorectal cancer
are for the most part metachronous with a free survival
period varying between 3 months and 11 years with an
average of 4 years [8] and a disease-free survival rang-
ing from 6 months to 7 years following splenectomy for
metachronous lesions with colorectal cancer [9]. Five of
the 30 cases reported in literature had a progression of
the disease characterized by the onset of liver, peritone-
al and lymph-node metastasis over a period between 6
and 24 months.
Such slow disease progression could be a direct conse-
quence of immunological surveillance that makes it difficult
for the engraftment and growth of tumor cells in the spleen
[10, 11].
In addition, in our case, primary tumor was in the
left colon as described more frequently in the literature.
It was a stage III adenocarcinoma and the single splenic
metastasis discovered after 28 months after surgery but
without an increase in the serum CEA level. Our patient
also showed a saccular dilatation of splenic which might
have favored, by slowing the blood flow, the seeding of
tumor cells in the splenic parenchyma. We can conclude
that, in the absence of further lesions, splenectomy was
indicated.
Because of the small number of cases reported in the liter-
ature and the absence of long-term follow-up data, a standard
systemic treatment for splenic metastasis from individual co-
lorectal cancer cannot be established.
Fig. 1 Macroscopic view of the splenectomy specimen with colon
cancer metastasis
Fig. 2 Histological section of
splenic parenchyma (a) infiltrated
by a neoplastic glandular
proliferation consistent with
metastatic adenocarcinoma (b)
(original magnification ×40;
hematoxylin-eosin)
J Gastrointest Canc
RE
VIS
ED
 PR
OO
F
Compliance with Ethical Standards
Informed Consent Informed consent was obtained from the individual
described in this report.
Conflict of Interest The authors declare that they have no competing
interests.
References
1. Griffin N, Burke C, Grant LA. Common primary tumours of the
abdomen and pelvis and their patterns of tumour spread as seen on
multi-detector computed tomography. Insights Imaging. 2011;2(3):
205–14.
2. Abi Saad GS, Hussein M, El-Saghir NS, Termos S, Sharara AI,
Shamseddine A. Isolated splenic metastasis from colorectal cancer.
Int J Clin Oncol. 2011;16:306–13.
3. Berge T. Splenic metastases. Frequencies and patterns. Acta Pathol
Microbiol Scand A. 1974;82(4):499–506.
4. Bigot P, Goodman C, Hamy A, Teyssedou C, Arnaud JP. Isolated
splenic metastasis from colorectal cancer: report of a case. J
Gastrointest Surg. 2008;12(5):981–2.
5. Thomas SM, Fitzgerald JB, Pollock RE, Evans DB. Isolated
splenic metastases from colon carcinoma. Eur J Surg Oncol.
1993;19(5):485–90.
6. Indudhara R, Vogt D, Levin HS, Church J. Isolated splenic metas-
tases from colon cancer. South Med J. 1997;90(6):633–6.
7. Teixeira CR, Tanaka S, Haruma K, Yoshihara M, Sumii K,
Kajiyama G, et al. Carcinoembryonic antigen staining patterns at
the invasive tumor margin predict the malignant potential of colo-
rectal carcinoma. Oncology. 1994;51(3):228–33.
8. Avesani EC, Cioffi U, De Simone M, Botti F, Carrara A, Ferrero S.
Synchronous isolated splenic metastasis from colon carcinoma. Am
J Clin Oncol. 2001;24(3):311–2.
9. Weathers BK, Modesto VL, Gordon D. Isolated splenic metastasis
from colorectal carcinoma: report of a case and review of the liter-
ature. Dis Colon Rectum. 1999;42(10):1345–8.
10. Kim JC, Jeong CS, Kim HC, Yu CS, Kang GH, Lee MG. Isolated
splenic metastasis from colorectal carcinoma: a case report. J
Korean Med Sci. 2000;15(3):355–8.
11. Cappello F, Conway de Macario E, Marino Gammazza A,
Bonaventura G, Carini F, Czarnecka AM, et al. Hsp and human
aging: les liaisons dangereuses. Front Biosci. 2013;18:626–37.
J Gastrointest Canc
